Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-09-14, Stock:ABBV, The news for the past five days is as follows:
2021-09-07: NEWS1: Top Analyst Reports for Facebook, AbbVie & 3M.
2021-09-08: NEWS1: AbbVie (ABBV) Gains As Market Dips: What You Should Know.NEWS2: Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio.NEWS3: AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress.
2021-09-09: NEWS1: Could This Label Expansion Be a Blockbuster for AbbVie's Shareholders?.NEWS2: AbbVie to Present at the Morgan Stanley Healthcare Conference.NEWS3: Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet.
2021-09-10: NEWS1: Downward Pressures and Flat Earnings Outweigh the AbbVie Inc.'s (NYSE:ABBV) Dividend Yield.NEWS2: AbbVie Declares Quarterly Dividend.NEWS3: 3 Stocks to Watch in September.NEWS4: AbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021.
2021-09-13: NEWS1: Regenxbio Stock Catapults To 7-Month High On AbbVie's $1.75 Billion Bet On Gene Therapy.NEWS2: Why Regenxbio Stock Is Way Up Today.NEWS3: Why Regenxbio Shares Are Trading Higher Today.NEWS4: AbbVie Nabs Eye Disease Gene Therapy From Regenxbio for Up to $1.8 Billion.NEWS5: AbbVie, RegenXBio Ink $1.75B Retinal Gene Therapy Collaboration.NEWS6: AbbVie's deal to develop Regenxbio's investigational gene therapy could be worth $1.8 billion.NEWS7: UPDATE 1-AbbVie, Regenxbio enter deal to develop retinal disease therapy.NEWS8: AbbVie and REGENXBIO Announce Eye Care Collaboration.

Answer: Decrease